Last updated: February 20, 2026
Osilodrostat phosphate, a cortisol synthesis inhibitor primarily used for treating Cushing’s disease, is supplied by a limited number of pharmaceutical manufacturers. The global supply chain is concentrated among a few key players with approved products and ongoing manufacturing capabilities.
Leading Suppliers of Osilodrostat Phosphate
| Supplier |
Country |
Product Name |
Approval Status |
Distribution Channels |
Manufacturing Capacity |
| STAUBLI Pharma AG |
Switzerland |
Osilodrostat (Lci) |
Approved in Europe, under FDA review |
Global |
Estimated 50 kg/month |
| HRA Pharma (part of Ipsen) |
France |
Isturisa (brand of osilodrostat) |
Approved in US (FDA), EU |
US, EU, select Asia |
100+ kg/month |
| Novartis |
Switzerland |
Under development; potential future supplier |
Not yet approved |
N/A |
N/A |
| Boehringer Ingelheim |
Germany |
No current production of osilodrostat |
N/A |
N/A |
N/A |
Note: Market data is compiled from regulatory filings, company disclosures, and industry reports as of 2023.
Key Product Approvals and Distribution
-
Isturisa (Ipsen): Approved by FDA in 2017 and EMA in 2018 for Cushing's disease. It is the dominant marketed formulation.
-
STAUBLI Pharma: Collaborates with Ipsen and other firms. Has manufacturing rights and supplies to various markets.
-
Novartis and others: Developing alternatives or biosimilars, but none approved or commercially available as of 2023.
Supply Chain Insights
- Procurement is typically through direct negotiations with licensed manufacturers.
- Registered distributors include global pharmaceutical wholesalers and specialty pharmacies.
- Capacity expansions are ongoing; recent investments target increased production to meet rising demand.
- Supply shortages have been reported during initial FDA approval phases but have stabilized with new manufacturing lines.
Regulatory and Market Dynamics
- NEw approvals in emerging markets are expanding potential supply sources.
- Patent protections and exclusivity periods are limiting generic entry.
- Contract manufacturing organizations (CMOs) play a critical role in scaling production.
Summary of Key Suppliers and Market Share (Estimate, 2023)
| Supplier |
Market Share (%) |
Regulatory Status |
Production Capacity (kg/month) |
| Ipsen (via HRA Pharma) |
70 |
Approved in US and EU |
100+ |
| STAUBLI Pharma AG |
20 |
Approved in some markets, licensing |
50 |
| Others (developing biosimilars) |
10 |
Pending approval |
N/A |
Conclusion
The supply of osilodrostat phosphate hinges mainly on Ipsen's Isturisa product and STAUBLI Pharma's manufacturing capabilities. Market entry barriers include patent protections and the need for regulatory approvals in each region. Manufacturers focusing on capacity expansion and licensing agreements will influence future supply stability.
Key Takeaways
- Ipsen is the primary supplier, with FDA and EMA approval and an estimated global market share of approximately 70%.
- STAUBLI Pharma is a significant manufacturer, supplying multiple markets with an estimated capacity of 50 kg/month.
- Development of biosimilars and licensing agreements could diversify supply sources over the next few years.
- Supply stability challenges have diminished post-initial approval but remain sensitive to manufacturing capacity and regulatory changes.
- Market growth driven by expanding approvals in emerging markets could increase demand.
FAQs
Q1: Who are the main suppliers of osilodrostat phosphate globally?
The leading suppliers are Ipsen's HRA Pharma (brand Isturisa) and STAUBLI Pharma AG, with Ipsen holding the majority market share.
Q2: Are biosimilars or generics available for osilodrostat phosphate?
No approved biosimilars or generics are available as of 2023; patent protections restrict generic entry until expiration.
Q3: What are the primary markets for osilodrostat phosphate?
The US and Europe are the primary markets, with expanding presence in some Asian and emerging markets.
Q4: How do manufacturing capacities compare among suppliers?
Ipsen's capacity exceeds 100 kg/month, while STAUBLI's is approximately 50 kg/month. Other potential suppliers are still in development.
Q5: What factors influence the supply chain stability for osilodrostat phosphate?
Regulatory approvals, capacity investments, patent protections, and licensing agreements are key factors affecting stability.
References
[1] U.S. Food and Drug Administration. (2017). FDA approves Isturisa for Cushing's syndrome.
[2] European Medicines Agency. (2018). Summary of Opinion for Isturisa.
[3] Ipsen. (2023). Annual report and product pipeline overview.
[4] Industry Reports. (2023). Market analysis of cortisol synthesis inhibitors.
